Mirabegron &Ndash; A Selective &Szlig;3-Adrenoreceptor Agonist for the Treatment of Overactive Bladder

Research and Reports in Urology - New Zealand
doi 10.2147/rru.s28930
Full Text
Abstract

Available in full text

Categories
Urology
Date
Authors
Publisher

Informa UK Limited

Related search

Mirabegron: A Beta-3 Agonist for Overactive Bladder

The Consultant Pharmacist
2014English

Discovery of Vibegron: A Potent and Selective 3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder

English

Persistence and Adherence With Mirabegron, a New Beta-3 Receptor Agonist, Versus Antimuscarinics in Overactive Bladder: Early Experience in Canada

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

AE9C90CB: A Novel, Bladder-Selective Muscarinic Receptor Antagonist for the Treatment of Overactive Bladder

British Journal of Pharmacology
Pharmacology
2010English

The Effect of Mirabegron, Used for Overactive Bladder Treatment, on Female Sexual Function: A Prospective Controlled Study

BMC Urology
MedicineReproductive MedicineUrology
2018English

OnabotulinumtoxinA for the Treatment of Overactive Bladder

Research and Reports in Urology
Urology
2014English

Botulinum Toxin a for the Treatment of Overactive Bladder

Toxins
MutagenesisToxicologyHealth
2016English

New Developments in the Management of Overactive Bladder: Focus on Mirabegron and onabotulinumtoxinA

Therapeutics and Clinical Risk Management
2013English

Long-Term Safety and Efficacy of the Novel Β3 -Adrenoreceptor Agonist Vibegron in Japanese Patients With Overactive Bladder: A Phase III Prospective Study

International Journal of Urology
Urology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy